Zacks Research Issues Pessimistic Forecast for BAX Earnings

Baxter International Inc. (NYSE:BAX - Free Report) - Zacks Research cut their Q1 2025 EPS estimates for Baxter International in a research report issued on Thursday, March 13th. Zacks Research analyst I. Bandyopadhyay now anticipates that the medical instruments supplier will earn $0.49 per share for the quarter, down from their previous estimate of $0.50. The consensus estimate for Baxter International's current full-year earnings is $2.48 per share. Zacks Research also issued estimates for Baxter International's Q2 2025 earnings at $0.60 EPS, Q3 2025 earnings at $0.66 EPS, Q1 2026 earnings at $0.52 EPS, Q2 2026 earnings at $0.65 EPS, Q3 2026 earnings at $0.73 EPS, FY2026 earnings at $2.63 EPS and FY2027 earnings at $2.82 EPS.

Several other brokerages have also commented on BAX. Citigroup lowered their price objective on Baxter International from $37.00 to $35.00 and set a "neutral" rating for the company in a research report on Wednesday, December 11th. Argus raised shares of Baxter International from a "hold" rating to a "buy" rating in a research report on Monday, February 24th. JPMorgan Chase & Co. dropped their price target on Baxter International from $38.00 to $36.00 and set a "neutral" rating for the company in a research note on Friday, February 21st. Barclays increased their target price on Baxter International from $39.00 to $41.00 and gave the company an "overweight" rating in a research report on Monday, March 10th. Finally, The Goldman Sachs Group initiated coverage on Baxter International in a research report on Wednesday, February 26th. They issued a "buy" rating and a $42.00 price target for the company. One research analyst has rated the stock with a sell rating, five have assigned a hold rating and five have assigned a buy rating to the stock. According to MarketBeat.com, Baxter International currently has an average rating of "Hold" and an average price target of $38.56.

Remove Ads

Baxter International Trading Down 1.4 %

Shares of Baxter International stock traded down $0.49 on Monday, hitting $33.61. The stock had a trading volume of 2,989,959 shares, compared to its average volume of 4,232,120. The stock's 50-day simple moving average is $32.75 and its two-hundred day simple moving average is $33.90. Baxter International has a one year low of $28.34 and a one year high of $43.99. The stock has a market cap of $17.19 billion, a price-to-earnings ratio of -26.23, a PEG ratio of 0.93 and a beta of 0.60. The company has a quick ratio of 1.09, a current ratio of 1.43 and a debt-to-equity ratio of 1.31.

Baxter International (NYSE:BAX - Get Free Report) last announced its quarterly earnings results on Thursday, February 20th. The medical instruments supplier reported $0.58 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.52 by $0.06. Baxter International had a negative net margin of 5.05% and a positive return on equity of 16.67%. The firm had revenue of $2.75 billion for the quarter, compared to the consensus estimate of $2.67 billion.

Institutional Trading of Baxter International

A number of hedge funds have recently added to or reduced their stakes in BAX. CoreFirst Bank & Trust purchased a new position in Baxter International during the fourth quarter worth $26,000. Riverview Trust Co boosted its stake in shares of Baxter International by 5,488.2% during the 4th quarter. Riverview Trust Co now owns 950 shares of the medical instruments supplier's stock worth $28,000 after acquiring an additional 933 shares in the last quarter. LRI Investments LLC lifted its holdings in shares of Baxter International by 60.8% in the third quarter. LRI Investments LLC now owns 1,560 shares of the medical instruments supplier's stock valued at $59,000 after purchasing an additional 590 shares in the last quarter. CKW Financial Group raised its holdings in shares of Baxter International by 100.0% during the third quarter. CKW Financial Group now owns 2,200 shares of the medical instruments supplier's stock worth $81,000 after acquiring an additional 1,100 shares in the last quarter. Finally, Bruce G. Allen Investments LLC raised its holdings in shares of Baxter International by 247.3% during the fourth quarter. Bruce G. Allen Investments LLC now owns 2,622 shares of the medical instruments supplier's stock worth $76,000 after acquiring an additional 1,867 shares in the last quarter. 90.19% of the stock is owned by institutional investors and hedge funds.

Baxter International Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, April 1st. Investors of record on Friday, February 28th will be given a $0.17 dividend. The ex-dividend date of this dividend is Friday, February 28th. This represents a $0.68 dividend on an annualized basis and a dividend yield of 2.02%. Baxter International's dividend payout ratio (DPR) is presently -53.13%.

Baxter International Company Profile

Baxter International Inc, through its subsidiaries, develops and provides a portfolio of healthcare products worldwide. The company operates through four segments: Medical Products and Therapies, Healthcare Systems and Technologies, Pharmaceuticals, and Kidney Care. The company offers sterile intravenous (IV) solutions; infusion systems and devices; parenteral nutrition therapies; generic injectable pharmaceuticals; surgical hemostat and sealant products, advanced surgical equipment; smart bed systems; patient monitoring and diagnostic technologies; and respiratory health devices, as well as advanced equipment for the surgical space, including surgical video technologies, precision positioning devices, and other accessories.